Peri-lymphatic cytokines (IRX-2) as immunologic induction preceding neoadjuvant chemo-immunotherapy in

Alan Su1, Erin C Hong1, Nicole Moxon1

  • 1Earle A. Chiles Research Institute, Providence Cancer Institute, Portland, OR, USA.

NPJ Breast Cancer
|March 18, 2026
PubMed

We previously showed the feasibility and immunologic effects of multivalent peri-lymphatic cytokine injection (IRX-2) in early-stage breast cancer. We now report outcomes of a pilot evaluation of IRX-2 + pembrolizumab induction preceding neoadjuvant chemo-immunotherapy in triple-negative breast cancer (TNBC). Single-cycle induction was associated with radiographic tumor regression, tumor necrosis, immune infiltration, and high pathologic complete response rate following platinum-sparing chemo-immunotherapy. Further investigation of peri-lymphatic cytokines in TNBC is warranted.

Related Concept Videos